share_log

Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.

Benzinga ·  Dec 19, 2024 09:34
Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment